肿瘤预防与治疗2024，Vol.37Issue(9)：793-799,7.DOI:10.3969/j.issn.1674-0904.2024.09.009
CLDN18.2在胃癌中的研究进展
Research Progress of CLDN18.2 in Gastric Cancer
摘要
Abstract
Gastric cancer,as one of the common malignant tumors,has high heterogeneity,lacks relevant therapeutic targets,and has a poor prognosis.As a membrane protein in the paracellular tight junction structure,CLDN18.2,which is only expressed in the differentiated epithelial cells of the gastric mucosa,has a high degree of specificity,and is expected to be a potential target for targeted therapy of gastric cancer.Zolbetuximab,a monoclonal antibody against CLDN18.2,directly used or combined with chemotherapy,has achieved good therapeutic efficacy in the initial clinical trials.CLDN18.2-targeted therapeutic regimens such as CAR-T cells,antibody-drug conjugate and biclonal antibodies have achieved preliminary suc-cess in the basic experiments,which need to be further verified in the clinical trials.In this article,we summarized the re-sults of previous studies and clinical trials related to CLDN 18.2 in gastric cancer,with the aim of providing evidence for clin-ical and translational research on CLDN18.2-positive gastric cancer.关键词
CLDN18.2/胃癌/靶向治疗/研究进展Key words
CLDN18.2/Gastric cancer/Targeted therapy/Research progress分类
医药卫生引用本文复制引用
张兴玉,陈静,肖军,赵丽丽,臧建华,龙麟,孙金芳..CLDN18.2在胃癌中的研究进展[J].肿瘤预防与治疗,2024,37(9):793-799,7.基金项目
山东省中医药重点学科建设项目(编号:2022-3) （编号:2022-3）
2022年度山东省中医药科技项目(编号:Q-2022009) （编号:Q-2022009）
青岛市临床重点专科建设项目(攀峰学科)(编号:2022-10) This study was supported by grants from Health Commission of Shandong Province(No.2022-3,No.Q-2022009)and Qingdao Municipal Health Commission(No.2022-10). （攀峰学科）
